Australia, New Zealand (NZ), and Singapore all experience regular influenza seasons that coincide with winter in the Southern Hemisphere. After pandemic influenza A(H1N1) 2009 (A\[H1N1\]pdm09) emerged during spring in North America ([@R1]), influenza notifications and other markers of influenza activity peaked in Australia, NZ, and Singapore during July 2009 ([@R2]--[@R4]). The 3 countries continued to experience the circulation of an influenza strain closely related to the original virus until at least the following winter ([@R5]).

Most influenza surveillance systems are passive, laboratory-based systems that capture only symptomatic patients who seek medical advice and are then appropriately tested and case notifications sent. Therefore, these systems are likely to underestimate the true attack rate. Measurement of antibodies against A(H1N1)pdm09 can be used to assess the extent of population exposure to the virus ([@R6]). The emergence of a novel influenza virus provided a unique opportunity to study the behavior of influenza viruses to better understand their differential effects across various population groups.

Standardization of epidemiologic and serologic techniques across our region enabled more direct comparison of the effects of pandemic influenza on the different populations studied. Three of the countries in our region performed such studies, with publications originating from Australia ([@R7]--[@R15]), NZ ([@R16]), and Singapore ([@R17]). We pooled individual-level serologic data from studies that used the hemagglutination inhibition (HI) assay to describe the effects of the 2009 winter influenza pandemic in the Southern Hemisphere.

Methods
=======

Identification of Studies
-------------------------

A working group for pandemic influenza serologic studies was formed with assistance from the Australian Seasonal Influenza Surveillance Strategy Working Group. The aims of this group included standardization of methods to facilitate analysis of pandemic serosurveillance research undertaken across Australia. The group convened its first teleconference on September 29, 2009, and continued to meet regularly as the studies were performed. Through this group and its contacts, 11 teams of researchers were identified who had performed serologic studies. After expressions of interest from researchers in Singapore (which lies just north of the equator but has a mid-year peak in influenza notifications) and NZ, 2 additional groups were identified.

Additionally, we searched Embase and PubMed for the period January 2009 to April 2011 using a combination of database-specific controlled vocabulary and general free text terms, including the following: "influenza A virus, H1N1 subtype," "seroepidemiologic studies," "influenza," "seroepidemiology," "serosurvey," and geographic terms for regions of the Southern Hemisphere. No further studies were identified by using these search strategies.

Inclusion Criteria
------------------

Studies were eligible for inclusion if they assessed serologic immunity against A(H1N1)pdm09 by HI assay across a population group in the Southern Hemisphere or Singapore. Studies were eligible if collected before vaccination programs against the virus commenced or if strategies were in place to allow for vaccine effect. Investigators from contributing studies provided HI assay titers, collection date, age, and geographic location at the individual level. The Figure shows the study profile.

Pandemic Phases
---------------

We defined the study region as NZ, Singapore, or Australian state or territory. Because the definition of pandemic phases varied between included studies, we defined pandemic phases using generally more stringent criteria than those used in contributing studies. Prepandemic specimens were defined as those collected before the first notified case in the corresponding region. Postpandemic phases were defined using notification data from NZ and the Australian Government Department of Health and Ageing by week and region. For these countries, we defined postpandemic specimens as those collected at least 2 weeks after the date on which 90% of 2009 laboratory notifications had occurred for the region. In Singapore, continuing pandemic activity was noted through late 2009. Because the adult studies from Singapore were repeated collections from prospective cohorts, the latest collection was used for estimates of postpandemic immunity, generally from October 2009. The postpandemic collection from children in Singapore was from September 1, 2009, to June 2, 2010, and all of these specimens were included as postpandemic. Specimens that did not meet criteria for prepandemic or postpandemic were defined as intrapandemic and excluded from further analysis.

Statistical Analysis
--------------------

Most studies were performed as cross-sectional or analysis of continuous prospective collections of available specimens collected for other purposes. Studies that used a purposive sampling technique were analyzed in the same way as those that used convenience collections. In the case of cohort collections and clinical trials, pre- and postpandemic assays from the same person were delinked and analyzed independently for consistency with other study techniques. For clinical trials, preintervention data from the intervention group and all data from the control group were included, whereas postintervention data from the treatment group were excluded. One study (M) used a postpandemic, cross-sectional design with retrospective assessment of prepandemic titers for those specimens found to be seropositive. For this study, only the postpandemic collection was included.

All studies used 2-fold serial dilutions from an initial dilution of 1:10 to determine titers. A titer of [\>]{.ul}40 was used to define seropositivity because all included studies used this cutoff value. Two studies (L, O) reported the geometric mean of 3 assays for each specimen, and for these studies, geometric mean titers of [\>]{.ul}40 were used to define seropositivity. Seropositive proportions are expressed as the proportion of reciprocal titers [\>]{.ul}40, with 95% CIs. Seropositive proportions are only reported for groups represented by [\>]{.ul}20 specimens. For comparability, age-standardized assessments of the proportion seropositive were calculated, weighted by 5-year age brackets to a reference population (Australian population on June 1, 2009) ([@R18]). Attack rates are calculated (for populations for which pre- and postpandemic seropositive proportions were available) as the difference in proportions of the immune population between pre- and postpandemic groups, age-standardized to the same reference population.

Using data from the 11 community-based studies, we performed multivariate logistic regression for the outcome of seropositivity in pre- and postpandemic phases. Exposure variables included in the model consisted of sex, age group, and study region because no other variables were consistently available across datasets.

To quantify the effect of study methods and the presence of potential risk factors on seropositivity, we compared pairs of studies performed in similar populations, using multivariate logistic regression, on the outcome of seropositivity. Data from the reference study were included along with data from a study of persons with the most similar characteristics. Exposure variables consisted of age, sex, and the binary variable of comparison group versus reference group. Analyses were restricted to specimens taken from patients during the same pandemic phase with comparable demographic characteristics (age, region, and population). Data management and statistical analysis were carried out with Stata 11.0 (StataCorp LP, College Station, TX, USA).

Results
=======

Datasets were received from 11 groups of investigators, consisting of data from 10 published and 3 unpublished studies. Data were received from NZ, Singapore, and New South Wales (NSW), the Northern Territory (NT), Queensland, Tasmania, Victoria, and Western Australia in Australia. Datasets are listed by study design and population, with pandemic phases referring to investigators' definitions, which resulted in 19 datasets for analysis. Study designs consisted of 4 prospective cohorts (E--H), 3 randomized controlled trials (L, O, R), 2 prepandemic cross-sectional studies (A, D), 1 retrospective cohort study (M), and 6 unpaired pre-and postpandemic cross-sectional studies (I, J, K, N, P, S). Eleven datasets were community based, whereas 8 were from groups with potential risk factors.

Laboratory techniques common to all studies included HI assay, per inclusion criteria, and use of egg-grown, β-propiolactone--inactivated A/California/07/2009 reference virus as the antigen source. All studies provided titers and patient's age in years for each assay, and all Australian studies provided geographic data to at least state/territory level. [Table 1](#T1){ref-type="table"} illustrates study characteristics that differed between included studies, with studies differing by design, enrolment criteria, specimen type, and specific HI method. All studies but 2 (I, K) provided data on patient's sex for all assays. All studies attempted to avoid contamination of specimens from vaccination effect, but approaches used to achieve this differed.

###### Characteristics of collections included in database to estimate population attach rates of influenza A (H1N1) 2009 in the Southern Hemisphere, winter 2009\*

  Code (ref. no.)                                 Study design                                                                 No. assays by redefined phase   Population                                          Age range, y†   Study exclusions                                        Enrolment                                                              Region                                                                      Spec-imen type                    Testing lab-oratory   RBC species         Control serum specimen                    Monovalent pandemic vaccine effect                                          Notes and exclusions for analysis
  ----------------------------------------------- ---------------------------------------------------------------------------- ------------------------------- --------------------------------------------------- --------------- ------------------------------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------- --------------------------------- --------------------- ------------------- ----------------------------------------- --------------------------------------------------------------------------- ----------------------------------------------------------
  A ([@R16])                                      Pre cross-section                                                            524 pre                         Outpatients                                         1--99           None                                                    Opportunistic from stored specimens                                    NZ                                                                          Serum                             ESR                   Guinea pig          Human and ferret                          Not applicable                                                              None
  B ([@R16])                                      Post cross-section                                                           1,147 post                      Primary care patients                               1--89           None                                                    Active recruitment of registered GP patients                           NZ                                                                          Serum                             ESR                   Guinea pig          Human and ferret                          Collection prior to vaccination program                                     None
  C ([@R16])                                      Post cross-section                                                           532 post                        Health care workers‡                                21--109         None                                                    Active recruitment of hospital and clinic staff                        NZ                                                                          Serum                             ESR                   Guinea pig          Human and ferret                          Collection prior to vaccination program                                     None
  D ([@R7])                                       Pre cross-section                                                            152 pre                         Residents of aged-care facilities‡                  59--100         None                                                    Outbreak investigations of non-H1N1 viruses                            NSW                                                                         Serum                             CIDMLS                Human, O negative   Human                                     Not applicable                                                              None
  E ([@R17])                                      Prospective cohort (pre and post collections)                                788 pre                         Community residents                                 21--74          None                                                    Sub-cohort of existing cohort collection                               Singapore                                                                   Serum                             WHO-CC                Turkey              Human and ferret                          Collection prior to vaccination program                                     None
  671 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  F ([@R17])                                      689 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Prospective cohort (pre and post collections)   1 pre                                                                        Healthcare workers‡             20--67                                              None            Email and word of mouth staff recruitment at hospital   Singapore                                                              Serum                                                                       WHO-CC                            Turkey                Human and ferret    Collection prior to vaccination program   None                                                                        
  1,138 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  391 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  G ([@R17])                                      Prospective cohort (pre and post collections)                                300 intra                       Staff and residents of long-term care facilities‡   19--109         None                                                    Active recruitment by invitation                                       Singapore                                                                   Serum                             WHO-CC                Turkey              Human and ferret                          Collection prior to vaccination program                                     None
  250 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  H ([@R17])                                      Prospective cohort (pre and post collections)                                1,915 intra                     Military personnel‡                                 18--62          None                                                    Active recruitment by invitation                                       Singapore                                                                   Serum                             WHO-CC                Turkey              Human and ferret                          Collection prior to vaccination program                                     None
  637 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  I ([@R8])                                       Pre and post cross-sections                                                  447 pre                         Community residents                                 0--19           Respiratory infection indication for testing            Opportunistic from pathology laboratory                                WA                                                                          Serum                             WHO-CC                Turkey              Human and ferret                          Collection prior to vaccination program                                     Gender unavailable
  221 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  229 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  J ([@R8])                                       Pre and post cross-sections                                                  201 pre                         Pregnant women‡                                     21--45          Respiratory infection indication for testing            Opportunistic from pathology laboratory                                WA                                                                          Serum                             WHO-CC                Turkey              Human and ferret                          Collection prior to vaccination program                                     None
  170 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  116 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  K ([@R9])                                       Pre and post- cross-sections                                                 474 pre                         Outpatients                                         0--100          Influenza serologic testing                             Opportunistic from pathology laboratories                              NSW                                                                         Serum or lithium-heparin plasma   CIDMLS                Human, O negative   Human                                     Collection prior to vaccination program                                     Gender unavailable for 164 pre-pandemic assays
  750 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  497 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  L ([@R10])                                      RCT of pandemic vaccine (pre-vaccine collection)                             166 intra                       Healthy adults                                      .               Pregnancy                                               Active recruitment of volunteers                                       Adelaide                                                                    Serum                             Focus                 Turkey              Human                                     Collection prior to vaccination program                                     Postvaccinationassays excluded
  M ([@R11])                                      Postpandemic cross-section with retrospective assessment of seroconversion   125 intra                       Persons infected with HIV‡                          19--77          None                                                    Opportunistic testing of specimens submitted for HIV load monitoring   NSW                                                                         Plasma                            CIDMLS                Human O-negative    Human                                     Collection prior to vaccination program                                     Retrospective assays excluded
  74 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  N ([@R12])                                      Pre and post cross-sections                                                  404 pre                         Blood donors                                        16--78          None                                                    Opportunistic collection from donated blood units                      Cairns, Townsville, Brisbane, Hobart, Melbourne, Newcastle, Perth, Sydney   Plasma                            WHO-CC                Turkey              Human and ferret                          Vaccination status checked if titer raised                                  None
  92 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  779 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  O ([@R13])                                      RCT of pandemic vaccine (pre-vaccine collection)                             290 intra                       Community volunteers                                0--8            Gestational age \<36 wk, investigational vaccine        Active recruitment through tertiary hospitals                          Adelaide, Brisbane, Melbourne, Perth, Sydney                                Serum                             Focus                 Turkey              Human                                     Collection prior to vaccination program                                     Postvaccination assays excluded
  73 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  P ([@R14])                                      Pre and post cross-sections                                                  443 pre                         Outpatients                                         0--97           None                                                    Opportunistic from pathology laboratory                                NT                                                                          Serum                             WHO-CC                Turkey              Human and ferret                          Collection prior to vaccination program                                     None
  2 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  1,689 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Q (unpub.)                                      Post cross-sections                                                          65 post                         Hemo-dialysis patients‡                             43--88          None                                                    Prevaccination blood sample                                            NSW                                                                         Serum                             CIDMLS                Human, O negative   Human                                     Collection prior to individual vaccination                                  None
  R (unpub.)                                      RCT of interferon (pre- and postintervention collections)                    64 pre                          Community volunteers                                20--74          Chronic respiratory conditions                          Active recruitment (email and newspaper)                               Perth                                                                       Serum                             WHO-CC                Turkey              Human and ferret                          Patients receiving vaccine excluded                                         Postintervention assays in active treatment arm excluded
  102 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  87 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  S (unpub.)                                      Pre and post cross-sections                                                  944 pre                         Community residents                                 0--18           None                                                    National pediatric serosurveillance studies                            Singapore                                                                   Serum                             WHO-CC                Turkey              Human and ferret                          Low vaccine uptake (≈1%--2%) in population at time of collection ([@R19])   Postvaccine assays excluded
  32 intra                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  460 post                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

\*RBC, red blood cells; pre, prepandemic phase; intra, intrapandemic phase; post, postpandemic phase; ESR, World Health Organization National Influenza Centre, Environmental Science and Research, New Zealand; CIDMLS, Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Sydney, Australia; WHO-CC, World Health Organization Collaborating Centre for Reference and Research on Influenza, North Melbourne, Australia; Focus = Focus Diagnostics, California, USA; RCT, randomized controlled trial; GP, general practitioner; NZ, New Zealand, NSW, New South Wales; WA, Western Australia; NT, Northern Territory. †Age range for specimens included in pre or postpandemic phases. ‡Defined as risk groups for analysis.

Received data consisted of 18,279 individual specimens, of which 18,131 assays (from 14,036 persons) were eligible for analysis, whereas 148 did not meet inclusion criteria. Samples were reclassified as prepandemic (4,414), intrapandemic (6,002), or postpandemic (7,715), according to the criteria described, with intrapandemic assays excluded from further analysis ([Figure](#F1){ref-type="fig"}). The timing of the pandemic phases and the sample taking is summarized in the [Technical Appendix](#SD1){ref-type="local-data"}. Of the assays eligible for analysis in the pre- or postpandemic groups, 125 prepandemic specimens and 2,065 postpandemic specimens were from risk groups, while the remainder were from community-based datasets.

![Flow chart showing profile of serologic studies to estimate attack rates of influenza A (H1N1) pandemic 2009 in the Southern Hemisphere during winter 2009.](11-1643-F){#F1}

[Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} show seropositive proportions in the pre- and postpandemic periods. Overall, the age-standardized prepandemic seropositive proportion was 9.4%, with regional estimates of 10.6% in Australia, 11.9% in NZ, and 3.5% in Singapore. Higher levels of immunity were seen with increasing age, with only 1 of 5 studies (A) of children finding evidence of preexisting immunity in age group 0--4 years, whereas markedly higher seropositive proportions were seen in those [\>]{.ul}75 years of age.

###### Prepandemic seropositive proportions by country, region, and risk group of influenza A (H1N1) 2009 in the Southern Hemisphere, winter 2009\*

  Code                    Pop.            Age groups, y          Sex           Overall                                     
  ----------------------- --------------- --------------- ------ ------ ------ --------- ------ -- ------ ------ -- ------ ------
  A, E, I, N, P, R, S     Overall         1.4             2.7    12.0   4.8    11.5      47.4      7.8    8.5       8.4    9.4
  I, N, P, R              AU              0               1.6    12.2   7.9    12.3      48.8      11.7   9.3       11.0   10.6
  A                       NZ              7.0             14.9   8.4    5.3    20.1      33.3      9.2    16.5      12.0   11.9
  E & S                   Sing            0               1.6    12.7   2.0    1.4                 2.2    3.3       4.7    3.5
  K                       NSW             0               5.1    14.2   4.4    24.6      51.9      15.1   9.5       19.6   11.9
  P                       NT              0               0      4.4    8.7    8.2       26.7      6.5    8.5       7.4    6.9
  N                       QLD                                    12.3   11.3   14.4                15.0   10.6      12.6   
  I, R                    WA              0               0      15.7   0      7.7                 12.5   4.2       4.7    9.8
  Risk group collection                                                                                                    
  D                       NSW res. care                                        28.0      50.5      55.8   23.7      46.0   

\*Pop., population; age-stand., age-standardized; AU, Australia; NZ, New Zealand; Sing, Singapore; NSW, New South Wales; QLD, Queensland; NT, Northern Territory; WA, Western Australia; res., residential. Blank cells indicate no data.

###### Postpandemic seropositive proportions by country, region, and risk group of influenza A (H1N1) 2009 in the Southern Hemisphere, winter 2009, with age-characterized AR\*

  -------------------------------------------------------- -------------------- --------------- -------- -------- ------- --------- --------------- --- ------ ------ ------------ ------ ------ ------
  Code                                                     Pop.                 Age groups, y            Sex              Overall   Age stand. AR                                                
  0--4                                                     5--14                15--34          35--54   55--74   ≥75               F               M          Raw    Age stand.                 
  A, B, E, I, K, N, O, P, R, S                             Overall              27.6            34.3     30.5     16.8    18.0      23.3                23.0   22.3                23.8   24.3   14.9
  I, K, N, O, P, R                                         AU                   24.0            32.2     29.8     17.8    18.8      17.0                23.3   21.2                23.1   23.7   13.1
  B                                                        NZ                   37.2            46.3     38.1     22.3    20.1      35.8                30.5   30.1                30.3   30.8   19.0
  E, S                                                     Sing.                24.5            29.6     17.2     11.0    6.8                           10.7   13.4                19.2   17.5   14.0
  K, N                                                     NSW                  17.3            18.4     37.8     19.3    18.8      21.6                25.5   24.2                26.2   27.2   15.3
  P                                                        NT                   16.7            37.2     22.0     18.1    16.3      14.3                20.5   18.3                19.5   21.8   15.0
  N                                                        QLD                                           29.6     9.3     14.8                          19.2   18.0                18.5          
  N                                                        Tas                                           35.9     28.9    26.7                          35.6   24.5                30.6          
  N, O                                                     Vic                  36.1                     30.8     12.5    21.4                          31.3   13.6                21.5          
  I, N, R                                                  WA                   24.0            39.5     31.6     18.2    34.3                          27.4   27.5                31.4   30.3   20.5
  Risk group collections                                                                                                                                                                         
  M                                                        NSW, HIV+                                              29.5    30.4                                 35.6                28.4          
  Q                                                        NSW, hemo.                                                     21.7      25.0                20.8   22.0                21.5          
  C                                                        NZ, HCWs                                      31.3     23.7    27.6      33.3                26.3   28.2                26.7          
  F                                                        Sing. HCWs                                    11.0     6.8     11.1                          10.1   6.3                 9.5           
  G                                                        Sing. res. care                               4.3      2.7     6.8       11.4                4.9    9.4                 6.8           
  H                                                        Sing. military                                35.7     3.4                                          34.5                33.9          
  J                                                        WA, preg. women                               13.3     19.2                                  14.7                       14.7          
  P                                                        NT, indig.                           37.5     28.4     28.1    32.9                          28.4   30.9                29.5   29.8   22.1
  B                                                        NZ, Maori                                     42.3     26.2    20.6                          39.4   28.0                34.3          
  B                                                        NZ, Pacific People   56.0            55.6     53.1     39.5    24.3                          43.6   45.1                43.7          
  Overall attack rates, community-based studies                                                                                                                                                  
  A, B, E, I, K, N, O, P, R, S                             Overall              26.2            31.6     18.5     12.1    6.4       --24.1              15.2   13.7                15.3   14.9   
  Overall geometric mean titers, community-based studies                                                                                                                                         
  A, E, I, N, P, R, S                                      Pre                  6.03            5.86     8.63     6.97    8.57      24.13               15.2   13.7                15.3   14.9   
  A, B, E, I, K, N, O, P, R, S                             Post                 15.42           16.87    16.09    10.10   11.29     14.74               15.2   13.7                15.3   14.9   
  -------------------------------------------------------- -------------------- --------------- -------- -------- ------- --------- --------------- --- ------ ------ ------------ ------ ------ ------

\*Results are expressed as % (95% CI). AR, attack rate; Pop., population; Age-stand, age-standardized; AU, Australia; NZ, New Zealand; Sing., Singapore; NSW, New South Wales; NT, Northern Territory; QLD, Queensland; Tas, Tasmania; Vic, Victoria; WA, Western Australia; HCWs, health care workers; hemo., hemodialysis; res., residential; preg., pregnant; indig., indigenous; pre, prepandemic; post, postpandemic. Blank cells indicate no data.

In the postpandemic period, the age-standardized seropositive proportion was 24.3%, giving an attack rate of 14.9% ([Table 3](#T3){ref-type="table"}). Attack rates by country were 13.1% for Australia, 19.0% for NZ, and 14.0% for Singapore. For all regions in which children 5--14 years of age were assessed, this age group had the highest levels of postpandemic seropositivity, except for NSW, in which those 15--34 years of age showed the greatest seropositivity. Among risk groups, unweighted seropositive proportions were 28.4% in HIV-positive persons in NSW, 21.5% in hemodialysis patients in NSW, 26.7% in NZ health care workers, 9.5% in Singaporean health care workers, 33.9% in Singaporean military personnel, 6.8% in staff and residents of Singaporean residential care facilities, 14.7% in pregnant women in WA, 29.5% in indigenous residents of the NT, 34.3% in Maori in NZ, and 43.7% in Pacific Peoples in NZ.

Logistic regression performed in assays from postpandemic, community-based collections showed that the age groups 5--14 years and 15--34 years, as well as residence in NZ, were associated with increased seropositivity. Negative effects were seen for older age groups and those with residence in Singapore ([Table 4](#T4){ref-type="table"}).

###### Multivariate logistic regression models on outcome of pre- and postpandemic seropositivity in community-based studies of influenza A (H1N1) 2009 in the Southern Hemisphere with exposure variables of region, age group, and sex, winter 2009\*

  Exposure variable    Prepandemic phase, n = 4,289             Postpandemic phase, n = 5,650                       
  -------------------- ------------------------------ --------- ------------------------------- ------------------- ---------
  Region                                                                                                            
  New South Wales†     1                                                                        1                   
  New Zealand          1.18 (0.77--1.80)              0.45                                      1.44 (1.17--1.79)   0.001
  Northern Territory   0.62 (0.38--1.02)              0.06                                      0.82 (0.66--1.01)   0.06
  Queensland           1.25 (0.79--1.98)              0.34                                      0.78 (0.53--1.14)   0.20
  Singapore            0.40 (0.27--0.61)              \<0.001                                   0.56 (0.43--0.74)   \<0.001
  Tasmania                                                                                      1.50 (0.95--2.35)   0.08
  Victoria                                                                                      1.37 (0.94--2.01)   0.11
  Western Australia    0.41 (0.25--0.67)              \<0.001                                   1.04 (0.76--1.43)   0.79
  Age group, y                                                                                                      
  0--4†                1                                                                        1                   
  5--14                2.34 (0.92--5.92)              0.07                                      1.60 (1.24--2.06)   \<0.001
  15--34               13.70 (5.85--32.07)            \<0.001                                   1.50 (1.18--1.91)   0.001
  35--54               6.24 (2.50--15.57)             \<0.001                                   0.75 (0.58--0.98)   0.04
  55--74               14.60 (5.98--35.62)            \<0.001                                   0.73 (0.56--0.95)   0.02
  ≥75                  47.43 (18.58--121.08)          \<0.001                                   0.95 (0.64--1.41)   0.80
  Sex                                                                                                               
  F†                   1                                                                        1                   
  M                    0.99 (0.73--1.34)              0.96                                      0.97 (0.85--1.24)   0.70
  Unknown              2.44 (1.74--3.42)              \<0.001                                   1.67 (1.25--2.24)   0.001

\*Blank cells indicate no data. The 2 regression models are displayed vertically. †Reference category.

In 2 instances, the same demographic group was assessed by 2 studies using different methods, allowing for assessment of the effect of study design. The 2 cross-sectional studies performed in adults in NSW in the postpandemic phase (performed in different laboratories) were included in a regression model that examined the effect of using serum specimens collected to identify pathologic agents from outpatients by comparing them to results with plasma units of donated blood. The 2 collections obtained from WA adults in the postpandemic phase were analyzed similarly to examine the effect of using volunteers in a randomized-controlled trial by comparing those results to results using plasma units of donated blood. Neither the use of opportunistically collected blood specimens nor the use of adults enrolled in randomized controlled trials showed a significant difference on the outcome of seropositivity from results using plasma units of donated blood ([Table 5](#T5){ref-type="table"}).

###### Multivariate logistic regression models comparing specific collections on outcome of seropositivity, with exposures of region, age group, and sex, in community-based studies of influenza A (H1N1) 2009 in the Southern Hemisphere, winter 2009\*

  Collections compared   No. assays included   Characteristics of model                                          ORs (95% CIs) for exposure variables                                                                                                   
  ---------------------- --------------------- -------------------------- -------------------------------------- -------------------------------------------------------------------- -- ------------------------------ ------------------------------- ------------------------------
  K                      N                     493                        Residence in NSW; post; age 16--78 y   Stored pathology specimens survey vs. survey of blood donors (NSW)      0.98 (0.65--1.49); p = 0.93    0.74 (0.66--0.84); p\<0.001     1.37 (0.89--2.09); p = 0.15
  R                      N                     204                        Residence in WA; post                  Patients voluntarily enrolled in RCT vs. blood donors (WA)              1.05 (0.56--1.98); p = 0.88    1.06 (0.86--1.31) p = 0.56      1.48 (0.79--2.79); p = 0.22
  D                      K                     278                        Pre; age ≥58 y                         Persons in res. care vs. community control group (NSW)                  0.49 (0.31--0.79); p = 0.003   2.79 (2.01--3.86); p\<0.001     0.34 (0.15--0.79); p = 0.01
  M                      K                     278                        Post; age 19--77 y                     Persons with HIV infection vs. community control group (NSW)            1.43 (0.80--2.57); p = 0.23    0.74 (0.61--0.90); p = 0.003    1.26 (0.66--2.41); p = 0.48
  Q                      K                     192                        Post; age 43--88 y                     Hemo. patients vs. community control group (NSW)                        0.90 (0.42--1.95); p = 0.79    0.91 (0.68--1.21); p = 0.50     1.65 (0.75--3.63); p = 0.21
  J                      N, R                  316                        Res. in WA; post; age 21--45 y         Preg. women vs. community control group (WA)                            .                              0.72 (0.48--1.06); p = 0.10     0.44 (0.24--0.81); p = 0.008
  C                      B                     1,316                      Post; age [\>]{.ul}21                  HCWs vs. community control group (NZ)                                   0.92 (0.70--1.22); p = 0.56    0.95 (0.88--1.03); p = 0.26     1.09 (0.83--1.42); p = 0.54
  F                      E                     1,080                      Post                                   HCWs vs. community control group (Sing.)                                1.12 (0.74--1.71); p = 0.59    0.78 (0.66--0.93); p = 0.006    0.65 (0.41--1.01); p = 0.06
  H                      E                     996                        Post; age 21--62                       Military personnel vs. community control group (Sing.)                  1.19 (0.75--1.88); p = 0.45    0.71 (0.58 -- 0.85); p\<0.001   0.97 (0.58--1.60); p = 0.89
  G                      E                     858                        Post                                   Res. care group vs. community control group (Sing.)                     1.38 (0.89--2.16); p = 0.15    0.81 (0.68--0.96); p= 0.02      0.44 (0.22--0.90); p = 0.03
  P                      P                     1,689                      Post                                   Aboriginal and Torres Strait Islanders vs. nonindig. people (NT)        0.95 (0.74--1.22); p = 0.68    0.88 (0.82--0.94); p\<0.001     2.67 (2.08--3.42); p\<0.001
  B                      B                     1,147                      Post                                   Maori vs nonindig. people (NZ)                                          0.95 (0.73--1.22); p = 0.66    0.86 (0.82--0.91); p \<0.001    1.17 (0.83--1.64); p = 0.38
  B                      B                     966                        Post                                   Pacific Peoples vs. nonindig. people (NZ)                               1.04 (0.78--1.37); p = 0.80    0.87 (0.82--0.92);p\<0.001      1.99 (1.41--2.82); p\<0.001

\*ORs, odds ratios; comp., comparison; ref., referent; NSW, New South Wales; post, postpandemic phase; WA, Western Australia; RCT, randomized controlled trial; pre, prepandemic phase; res., residence/residential; hemo., hemodialysis; preg., pregnant; HCWs, health care workers; NZ, New Zealand; NT, Northern Territory; nonindig., nonindigenous. The 13 regression models are displayed horizontally. †Age considered a continuous variable with OR for each decade of increasing age.

We compared several other pairs of datasets by logistic regression to examine the effect of specific risk factors on the outcome of seropositivity. The odds ratio for the binary variable of study of origin (comparison study vs. reference study) is displayed as an estimate of the effect of the risk factor on the outcome. In NSW during the prepandemic phase, living in a residential care facility was associated with lower levels of preexisting seropositivity than was living in the general community. However, in the postpandemic phase, we found that persons with HIV infection or those who were undergoing hemodialysis were not significantly more likely to be seropositive than were community control subjects. In WA in the postpandemic phase, pregnancy was associated with lower levels of seropositivity. Health care workers in NZ had levels of postpandemic seropositivity similar to community controls, but those of health care workers in Singapore were lower. In Singapore, military personnel had similar levels of postpandemic seropositivity, while staff and residents of residential care facilities had lower levels compared to community controls. Aboriginal and Torres Strait Islander residents of the NT had higher levels of postpandemic immunity than other ethnic groups, as did Pacific Peoples of NZ ([Table 5](#T5){ref-type="table"}).

Discussion
==========

We obtained estimates of the full epidemiologic effects of A(H1N1)pdm09 in the 2009 Southern Hemisphere winter by pooling data from several serologic studies performed across our region. We believe that population-based serologic studies give a more direct measure of community exposure to the virus than notification-based data, which are inherently limited by the proportion of cases of infection that are captured by the notification system. The individual-level data enabled us to apply consistent statistical methods across studies. This enabled estimates of seropositivity to be made across more directly comparable groups, as well as assessments of the effects of specific risk factors on seropositivity.

Our community-based, age-standardized estimates of prepandemic seropositive proportions ranged from 3.5% to 11.9%, with Singapore demonstrating a lower level of prepandemic immunity than Australia and NZ. The increased levels of prepandemic immunity in those [\>]{.ul}75 years of age are likely to be partially due to cross-reacting antibody responses to influenza A/South Carolina/1/1918 and related viruses that were circulating in the early 20th century ([@R20]). However, the steady increase in seropositivity with age across age groups suggests more recent circulation of influenza viruses with the potential to elicit cross-reacting antibody responses ([@R21]).

The finding of peak postpandemic seropositivity in the 5- to 14-year age group is consistent with greater social mixing of school-aged children, lower prepandemic immunity, and results from other population-wide studies ([@R22]*,*[@R23]). Despite the low level of prepandemic cross-reactive antibodies to the virus, Singapore remained the region with the lowest proportion of population-standardized seropositivity in the postpandemic phase (17.5%), whereas estimates from Australia and NZ ranged from 22.1% to 32.8%. The implication of lower postpandemic seropositivity in more tropical regions is consistent with estimates from India and Hong Kong ([@R23],[@R24]), as well as with the nonsignificant trend toward greater seropositivity in the more northerly Australian regions (NT and Queensland) on logistic regression. Although overall attack rates were similar for Australia and Singapore, this finding highlights the geographic heterogeneity of influenza spread and suggests that latitude may be a critical predictor of susceptibility to influenza, which might be explained by increased efficiency of transmission of influenza in cold temperatures ([@R25]) or population levels of vitamin D stores ([@R26]). The negative overall attack rate in those [\>]{.ul}75 years of age may have been an anomaly, because this age group had the smallest number of specimens and the prepandemic specimens were predominantly from NSW, while the postpandemic specimens were a combination of specimens from NSW, NZ, and NT. Other age groups had more similar compositions between pre- and postpandemic phases and so are likely to be more directly comparable. Alternative explanations include waning immunity in elderly persons in the months after seasonal influenza vaccination or limitations of study K, which observed the greatest decrease in titers in this age group.

Although several coexisting conditions have been found to be associated with severity of infection with A(H1N1)pdm09, most laboratory-confirmed cases across the Southern Hemisphere have occurred in persons without known risk factors ([@R27]). We found no increase in risk for postpandemic seropositivity among hemodialysis patients and a group of persons with generally well-controlled HIV infection. These results are consistent with the observation that HIV-infected patients admitted to a hospital for influenza have similar clinical outcomes as do non-HIV patients ([@R28]). Pregnant women represented ≈7%--9% of patients with laboratory-confirmed cases, severe infections, and admissions to intensive care units in the Southern Hemisphere ([@R27]). Although it has been postulated that this occurred because of the patients' younger ages and close contact with children, our results suggest that pregnancy is associated with a lower likelihood of infection, possibly because pregnant women actively avoid infection. Therefore, pregnant women appear more susceptible to severe illness with A(H1N1)pdm09 infection, which may relate to lower levels of immunoglobulin G~2~ ([@R29]). By contrast, our results suggest that the 6- to 7-fold higher rates of hospitalization seen in indigenous persons in our region are likely to be partially attributable to a higher attack rate in Australia ([@R30]). We did not find evidence for a higher attack rate among health care workers or military personnel, with levels of seropositivity comparable to those of the general community. A study in a Finnish garrison found that 22.3% of personnel had titers of [\>]{.ul}40, a level lower than the 33.9% observed in Singaporean military personnel postpandemic, even though this study was performed in response to a recent outbreak ([@R31]). Levels of seropositivity in those living in residential care appeared lower than in community-living persons of comparable age, both in a prepandemic comparison in NSW and in a postpandemic comparison in Singapore.

The unavoidable limitation to our comparisons is that they included data from multiple studies that used differing methods. Studies differed by epidemiologic approach, specimen type, and laboratory methods, and the jurisdictions studied exhibited different public health responses. We excluded from analysis data we considered to have been obtained with methods that were unlikely to give a population-wide estimate of serologic immunity, for example, 1 retrospective prepandemic collection from persons with postpandemic seropositivity (M) and the postintervention assessments from clinical trials (L, O, R, S). Several studies used convenience collections of specimens taken for clinical indications before routine discarding. These studies enabled population-based estimates but were subject to selection bias, given that conditions predisposing to influenza might increase the chance of being tested. By contrast, the use of blood donor specimens may select for a healthier sample. Cohort studies (E--H) were analyzed in the same manner as for cross-sectional surveys, although samples included in these datasets were determined by selection biases relating to original enrollment in the cohort as well as to enrollees dropping out. Previous evidence indicates that this is a valid approach to estimating population-wide immunity ([@R32]). Moreover, our analysis found no effect from differing study methods when comparing 2 pairs of studies performed in the same populations. Therefore, while the differences seen between the risk groups could have been caused by differences in study method, we found no evidence of this from the data available.

Whether the epidemiologic differences are due to differences in transmission in differing populations or because of the effectiveness of public health responses is difficult to gauge. In Australia, most jurisdictions moved from the Delay to the Contain phase on May 22 and from the Contain to the Protect phase on June 22. Only Victoria, which contributed 234 specimens to this pooled analysis, differed in the timing of its response phases ([@R33]). Although there were notable differences between public health management of the response to the outbreak in NZ and Singapore, the timing of the transition to containment was broadly similar, with NZ focusing primarily on containment from April 25 to June 21 ([@R34]), while Singapore began its transition to the Mitigation phase on June 29 ([@R35]).

Protocols for the HI assay may differ between laboratories in terms of specimen source and preparation (serum or plasma, erythrocyte adsorption), reagents (erythrocyte species, antigen preparation), procedure (incubation conditions), and controls. Furthermore, use of fresh erythrocytes for HI assays means inherent within-laboratory variability must be managed. To minimize variability between laboratory method and erythrocyte batches, control panels of serum samples were shared and results were standardized. A common source of virus antigen was also shared. Such comparative experiments were performed early in the pandemic between 3 of the 4 laboratories described in this analysis, with minimal variation seen. These 3 laboratories used a common source of A(H1N1)pdm09 antigen for at least 15 of the 19 datasets included. International standards were also available in 2009 for standardization of serologic assays around the world. Notably, the source of erythrocytes to detect influenza virus may vary, depending on the binding specificity of the hemagglutinin protein for each virus. A(H1N1)pdm09 virus recognized human, turkey, and guinea pig erythrocytes. This enabled laboratories to use cells that were available and that they were experienced in handling.

Although all studies used a titer of [\>]{.ul}40 as the cutoff for seropositivity, this is an over-simplification of the complex immune response to influenza infection, which includes both cellular and humoral components ([@R36]). Although a titer of 40 was achieved in 80%--90% of persons with PCR-confirmed infection with A(H1N1)pdm09 ([@R37]), in unpaired analysis, no single cutoff reliably determines past infection and subsequent immunity. Serologic studies that incorporated interviewing participants about symptoms of influenza-like illness suggest that as many as half of those with serum titers of [\>]{.ul}40 in the postpandemic phase do not have a history of a compatible illness ([@R16]*,*[@R31]). This finding partly reflects the fact that a proportion of those patients who were seropositive in the postpandemic phase were already seropositive in the prepandemic phase, but also suggests that some persons who seroconverted did not experience or report symptoms. Despite this, pre- and postpandemic cross-sectional serologic surveys are the most convenient and inclusive method for assessing population-wide serologic immunity.

Our results provide a broad picture of the effects of A(H1N1)pdm09 in the Southern Hemisphere during the winter of 2009. The absence of clear differences between estimates with different study methods suggests that pooling of data is likely to be useful in estimating the effects of the virus across population groups. We found greater levels of prepandemic seropositivity as patient's age increased, particularly in those [\>]{.ul}75 years of age. By contrast, in the postpandemic period, school-aged children showed the greatest levels of immunity. Health care workers, military personnel, persons with HIV infection, and hemodialysis patients had levels of postpandemic seropositivity similar to those of the general community. Pregnancy and residential care appeared protective from infection, suggesting more severe disease in those infected. Despite recording the lowest prepandemic levels of immunity, Singapore retained comparatively lower levels of seropositivity after the pandemic.

###### Technical Appendix

Provides dates samples collected in serologic studies and dates used to define pandemic phases in serologic studies.
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